Nandrolone Phenylpropionate 100mg/ml 10ml Vial by Genesis

Usage

1. Set your weekly cutting-phase target dose (typically 150–300mg/week) and divide by three to calculate your per-injection volume from the 100mg/ml vial.
2. Warm the vial briefly in the palm of the hand to reduce oil viscosity before drawing; this improves flow through the needle and ensures an accurate volume.
3. Wipe the rubber septum with a sterile alcohol swab before each draw; use a fresh needle for injection — never the draw needle.
4. Administer intramuscularly into the glute, vastus lateralis, or deltoid on your chosen three-day-per-week schedule, rotating sites to minimise local accumulation.
5. Track each injection date in a log to confirm consistent spacing — equal intervals across the week sustain plasma levels most relevant to cutting-phase anti-catabolism.
6. Re-refrigerate the vial promptly after each draw; at the end of the cycle or at 28 days post-opening (whichever comes first), discard remaining solution per local pharmaceutical waste guidelines.

Warnings

Frequently asked questions

Is Genesis Nandrolone Phenylpropionate 100mg/ml effective for a cutting phase?

Yes — nandrolone phenylpropionate is one of the most established anabolic compounds for cutting phases due to its anti-catabolic action, which defends lean muscle mass when caloric intake is reduced. The phenylpropionate ester clears quickly compared to longer-chain variants, giving users tighter cycle control. At 100–200mg per week, it supports nitrogen retention without introducing the excess water retention that conflicts with definition goals.

How do athletes structure NPP dosing within a cutting cycle?

Most cutting protocols split weekly NPP doses across three injection days — for example Monday, Wednesday, and Friday — to maintain consistent plasma levels without large fluctuations. Typical cutting-range doses run 150–300mg per week, lower than bulking doses, prioritising lean-tissue preservation over maximum hypertrophy. The 100mg/ml concentration of this Genesis vial allows clean measurement of 0.5ml and 1ml doses, keeping dose increments practical.

Which compounds are commonly stacked with NPP in cutting cycles?

For cutting, NPP is frequently paired with Testosterone Propionate (to maintain androgen baseline without long-ester water retention), Masteron (drostanolone propionate, for its anti-estrogenic and hardening effect), or Stanozolol (for vascularity and dry muscle appearance). Short-ester companions are preferred because they align clearance timelines, allowing all compounds to exit the system within a similar post-cycle window and enabling synchronised PCT initiation.

How should the 10ml vial be stored and handled after first use?

Once the rubber septum is first punctured, Genesis NPP 100mg/ml should be stored between 2°C and 8°C (refrigerated) and used within 28 days; the multi-dose vial design allows repeated clean draws with a fresh sterile needle each time, avoiding contamination of the remaining solution. Always inspect the oil for particulate matter or cloudiness before drawing. Keep the vial away from direct light and never freeze the contents.

Why does the 100mg/ml concentration offer an advantage for cutting versus higher-concentration NPP formulations?

The 100mg/ml concentration is the lowest in this comparative product group, which directly benefits cutting-cycle users who dose conservatively — 50mg increments correspond to just 0.5ml, a volume easily administered with a 1ml insulin-type syringe if preferred, minimising injection site discomfort. Higher-concentration formulations (150mg/ml and above) require smaller volumes per dose but reduce the resolution of small dose adjustments, making fine-tuning harder during a strict cut. (2) angle_used

Manufacturer

Genesis directs a dedicated proportion of its formulation development effort toward ester-specific optimisation — the understanding that different ester chains impose distinct solubility, viscosity, and crystallisation behaviours on the finished injectable product, and that a single generic oil-vehicle formulation cannot serve all of them equally well. For Nandrolone Phenylpropionate 100mg/ml, formulation development centred on identifying a carrier-oil-to-active-compound ratio that sustains full dissolution at the declared concentration across the vial's shelf-life without generating particulate matter at refrigerated storage temperatures — a stability challenge specific to phenylpropionate-chain compounds at moderate concentrations. Genesis's internal stability programme exposes finished-vial samples to accelerated temperature cycling, logging clarity, pH, and potency at defined intervals to confirm that the formulation meets specification not only at release but across the full declared shelf-life. This longitudinal stability dataset — rather than a single point-in-time test — is what Genesis cites as the technical foundation of its formulation confidence for this product.